Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks.

Pfizer Inc. (NYSE:PFE) reported its Q4 2025 results connected February 3. The institution posted gross of $17.56 billion, falling somewhat by 1.1% from a twelvemonth earlier. On the net call, Chairman and CEO Albert Bourla asserted that the institution closed retired 2025 connected a beardown footing, noting that execution passim the twelvemonth came successful up of its fiscal commitments. Pfizer bushed expectations connected some gross and adjusted diluted EPS and returned $9.8 cardinal to shareholders done dividends.

Looking to 2026, Bourla laid retired the company’s main priorities, which see getting much worth retired of caller acquisitions, advancing Pfizer’s obesity pipeline, and expanding the usage of artificial quality crossed the organization. He pointed to Seagen, Metsera, and Biohaven arsenic immoderate of the astir important deals Pfizer has made successful caller years, saying they person the imaginable to reshape the business. The absorption now, helium said, is connected afloat leveraging those portfolios and accelerating pipeline development.

Bourla besides highlighted advancement successful Pfizer’s obesity program, noting encouraging results from the VESPER-3 survey of its ultra-long-acting, next-generation injectable GLP-1 receptor agonist, antecedently known arsenic MET-097i.

Chief Financial Officer David Denton added that full-year 2025 gross came successful astatine $62.6 billion, down from $63.6 cardinal the twelvemonth before, reflecting a 2% operational decline. He emphasized that excluding COVID-19 products, operational gross grew 6% for the year. Denton besides said adjusted gross margins expanded to 76%, landing close wherever the institution expected.

Pfizer Inc. (NYSE:PFE) operates arsenic a research-driven planetary biopharmaceutical company, processing and commercializing medicines crossed oncology, superior care, and specialty areas for patients astir the world.

While we admit the imaginable of PFE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and 13 Best Long Term Low Risk Stocks to Buy Now

Disclosure: None.